Policy
FDA Wants Liquid Statin Off Shelves
The Brief
- The FDA wants the liquid simvastatin formulation FloLipid withdrawn from the market.
- The agency is giving the drugmaker an opportunity for a hearing before any final decision.
- Approval of the simvastatin oral suspension is at risk, according to MedPage Today's report.
Why it matters
If withdrawal goes ahead, patients and clinicians who rely on the liquid simvastatin form would need an alternative statin formulation.
Who’s affected
- patients who take liquid simvastatin
- physicians and pharmacists who prescribe or dispense simvastatin oral suspension
- #simvastatin
- #fda
- #drug approval
- #statins
- #pharmaceuticals
(MedPage Today) -- The FDA wants a liquid formulation of simvastatin (FloLipid) withdrawn from the market, though the agency is giving the drugmaker an opportunity for a hearing. Approval of simvastatin oral suspension is at risk because Salerno...